Author Archives: admin


Team applies new theory to learn how and why cells differentiate

Jun 16, 2014 An overview of the stem cell gene network gives a sense of the complex process involved in cell differentiation, as transcription factors and protein complexes influence and loop back upon each other. Rice University researchers found that stem cell differentiation can be defined as a many-body problem as they developed a theoretical system to analyze large gene networks. Credit: Bin Zhang/Rice University

How does a stem cell decide what path to take? In a way, it's up to the wisdom of the crowd.

The DNA in a pluripotent stem cell is bombarded with waves of proteins whose ebb and flow nudge the cell toward becoming blood, bone, skin or organs. A new theory by scientists at Rice University shows the cell's journey is neither a simple step-by-step process nor all random.

Theoretical biologist Peter Wolynes and postdoctoral fellow Bin Zhang set out to create a mathematical tool to analyze large, realistic gene networks. As a bonus, their open-access study to be published this week by the Proceedings of the National Academy of Sciences helped them understand that the process by which stem cells differentiate is a many-body problem.

"Many-body" refers to physical systems that involve interactions between large numbers of particles. Scientists assume these many bodies conspire to have a function in every system, but the "problem" is figuring out just what that function is. In the new work, these bodies consist not only of the thousands of proteins expressed by embryonic stem cells but also DNA binding sites that lead to feedback loops and other "attractors" that prompt the cell to move from one steady state to the next until it reaches a final configuration.

To test their tool, the researchers looked at the roles of eight key proteins and how they rise and fall in number, bind and unbind to DNA and degrade during stem cell differentiation. Though the interactions may not always follow a precise path, their general pattern inevitably leads to the desired result for the same reason a strand of amino acids will inevitably fold into the proper protein: because the landscape dictates that it be so.

Wolynes called the new work a "stylized," simplified model meant to give a general but accurate overview of how cell networks function. It's based on a theory he formed in 2003 with Masaki Sasai of Nagoya University but now takes into account the fact that not one but many genes can be responsible for even a single decision in a cellular process.

"This is what Bin figured out, that one could generalize our 2003 model to be much more realistic about how several different proteins bind to DNA in order to turn it on or off," Wolynes said.

A rigorous theoretical approach to determine the transition pathways and rates between steady states was also important, Zhang said. "This is crucial for understanding the mechanism of how stem cell differentiation occurs," he said.

Wolynes said that because the stem cell is stochasticthat is, its fate is not pre-determined"we had to ask why a gene doesn't constantly flip randomly from one state to another state. This paper for the first time describes how we can, for a pretty complicated circuit, figure out there are only certain periods during which the flipping can occur, following a well-defined transition pathway."

Read the rest here:
Team applies new theory to learn how and why cells differentiate

ReNeuron well set after 'transformational' year

ReNeuron Group Quote more

Price: 2.85

Chg: -0.17

Chg %: -5.47%

Date: 12:02

Stem cell treatment developer ReNeuron lost an increased 7.1m in a "transformational" year to end-March but still had plenty of cash in the bank as it moves into new cell manufacturing facility and files an investigational new drug (IND) application in the US early next year.

The AIM-listed company held cash outflow from operating activities roughly flat at 6m over the period, leaving cash, cash equivalents and bank deposits at period end of 20.92m, thanks to the 23.44m net fundraising in August 2013.

Chairman Bryan Morton said it was a transformational year for the business, both operationally and financially, as its lead stem cell therapy candidate for stroke entered Phase II clinical trials and the company began clinical development of a candidate for critical limb ischaemia.

He also noted that in both cases, and earlier-than-planned, ReNeuron gained regulatory approval to use a cryopreserved variant of its lead 'CTX' stem cell product line, which gives the treatments the potential to have "significant commercial and competitive advantages".

He confirmed the move to new cell manufacturing facility in South Wales early next year was on track, "which we believe will become a major element of ReNeurons overall value proposition".

Follow this link:
ReNeuron well set after 'transformational' year

KC area company developing stem cell treatments for pooches

KANSAS CITY, KS (KCTV) -

A KCK company is developing a stem cell treatment to help dogs deal with crippling pain from arthritis.

Aratana Therapeutics is working to treat osteoarthritis in pets via the stem cell treatment.

If the U.S. Food and Drug Administration approves, it would be the first treatment of its kind.

The treatment wouldn't provide a cure but would give much-needed relief.

"They're still able to move better but they can't do the things they did when they were younger," dog owner Rachel Thieme said.

Osteoarthritis can be quite debilitating for canines.

"It's really tough because may be there are other areas of quality of life that are fine. They are eating fine. They have that motivation but they just can't physically do anything, so sometimes you have to euthanize them," Thieme said.

The only way to cure the condition is to conduct a total joint replacement.

But the stem cell procedure hopefully will reduce the need for medications and therapies, said Kara Forsee, a veterinary surgeon for BluePearl Veterinary Partners.

See original here:
KC area company developing stem cell treatments for pooches

Scientists create an 'eye-in-a-dish' using human stem cells

Scientists copied processes that occur in the womb to create eye tissue Study used adult stem cells that have been genetically reprogrammed Lab-grown tissue responded to light the same way as it does in the eye The study represents a first step towards restoring sight in the blind

By Ellie Zolfagharifard

Published: 12:14 EST, 10 June 2014 | Updated: 14:02 EST, 10 June 2014

688 shares

5

View comments

A light-sensitive 'eye-in-a-dish' has been created by scientists using a type of human stem cell.

The three dimensional structure represents a first step towards restoring sight to the blind, say the researchers.

Processes that occur in the womb were copied to create complex retinal tissue in a laboratory petri dish.

A light-sensitive 'eye-in-a-dish' has been created by scientists in Maryland. The three dimensional structure represents a first step towards restoring sight to the blind, say the researchers. Pictured are the photoreceptors (in green) within a 'mini retina' structure (blue) that was created using human stem cells

Read more:
Scientists create an 'eye-in-a-dish' using human stem cells

Stem Cell Doctor at Beverly Hills Orthopedic Institute Now Offering Regenerative Procedures for Achilles Tendonitis …

Beverly Hills, CA (PRWEB) June 16, 2014

The top stem cell doctors at Beverly Hills Orthopedic Institute are now offering regenerative medicine procedures for Achilles tendonitis and tears. The procedures include options for several types of stem cell procedures that can provide pain relief and help patients avoid surgery. Call (310) 438-5343 for more information and scheduling.

Achilles tendonitis or tears may bother patients for many months and not respond well to traditional treatments. This may include NSAIDS, bracing and steroid injections. While surgery for these conditions may be extremely successful, there is often a considerable rehabilitation and potential surgery complications.

Stem cell injections for Achilles tears or tendonitis have been a revolutionary treatment. This may include bone marrow derived injections, or amniotic derived stem cell procedures. Both offer exceptional concentrations of stem cells, growth factors and additional reparative materials.

The procedures are performed as an outpatient, with the amniotic derived material coming from consenting donors after scheduled c-sections. There is no fetal material used, negating any ethical concerns.

Dr. Raj at Beverly Hills Orthopedic Institute is a Double Board Certified orthopedic doctor. He treats patients from weekend warriors to amateur and professional athletes, along with celebrities, executives, manual laborers and grandparents.

For more information and scheduling, call (310) 438-5343.

Follow this link:
Stem Cell Doctor at Beverly Hills Orthopedic Institute Now Offering Regenerative Procedures for Achilles Tendonitis ...

Systematic review

Background

Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined. We aimed to compare high-dose melphalan plus salvage ASCT with cyclophosphamide in patients with relapsed multiple myeloma who had previously undergone ASCT.

Between April 16, 2008, and Nov 19, 2012, 297 patients were registered, of whom 293 received PAD re-induction therapy. Between Aug 26, 2008, and Nov 16, 2012, 174 patients with sufficient PBSCs were randomised to salvage ASCT (n=89) or cyclophosphamide (n=85). After a median follow-up of 31 months (IQR 1942), median time to progression was significantly longer in the salvage ASCT than in the cyclophosphamide group (19 months [95% CI 1625] vs 11 months [912]; hazard ratio 036 [95% CI 025053]; p<00001). Frequently reported (in >10% of patients) grade 34 adverse events with PAD induction, salvage ASCT, and cyclophosphamide were: neutropenia (125 [43%] of 293 patients after PAD, and 63 [76%] of 83 patients in the salvage ASCT group vs 11 [13%] of 84 patients in the cyclophosphamide group), thrombocytopenia (150 [51%] after PAD, and 60 [72%] vs four [5%], respectively), and peripheral neuropathy (35 [12%] after PAD, and none vs none, respectively).

This study provides evidence for the improved efficacy of high-dose melphalan plus salvage ASCT when compared with cyclophosphamide in patients with relapsed multiple myeloma eligible for intensive therapy, which might help to guide clinical decisions regarding the management of such patients.

Read the original here:
Systematic review

KC area company developing stem cell treatments for pooches – Tucson News Now

KANSAS CITY, KS (KCTV) -

A KCK company is developing a stem cell treatment to help dogs deal with crippling pain from arthritis.

Aratana Therapeutics is working to treat osteoarthritis in pets via the stem cell treatment.

If the U.S. Food and Drug Administration approves, it would be the first treatment of its kind.

The treatment wouldn't provide a cure but would give much-needed relief.

"They're still able to move better but they can't do the things they did when they were younger," dog owner Rachel Thieme said.

Osteoarthritis can be quite debilitating for canines.

"It's really tough because may be there are other areas of quality of life that are fine. They are eating fine. They have that motivation but they just can't physically do anything, so sometimes you have to euthanize them," Thieme said.

The only way to cure the condition is to conduct a total joint replacement.

But the stem cell procedure hopefully will reduce the need for medications and therapies, said Kara Forsee, a veterinary surgeon for BluePearl Veterinary Partners.

Read the original here:
KC area company developing stem cell treatments for pooches - Tucson News Now

Cord blood infusion saves woman's life

LOS ANGELES (KABC) --

Amanda Canale doesn't take time with her daughter and niece for granted. She's just happy to feel good.

"I've been in the hospital, and I've been sick my whole life," Amanda said.

Amanda was born with a rare blood disorder that required daily shots.

"Basically, I have no white blood cells," Amanda said. "I have no immune system at all."

At 23, she developed leukemia and was given two weeks to live. She desperately needed a bone marrow transplant, but family members weren't matches. Her doctor suggested an umbilical cord blood transplant.

"The cord was a perfect match and it was available, so it was the right solution for her," Edward Agura, MD, Medical Director of Bone Marrow Transplantation, Baylor University Medical Center, Dallas, said.

Cord blood contains stem cells that regenerate. Mothers of newborns can save their child's own blood or donate it. More than 30,000 transplants have been performed worldwide. However, because the blood comes from a tiny newborn, there's not much of it.

"The cord blood is rare, precious and few, and yet is more potent in its ability to grow," Dr. Agura said.

Now, doctors at Baylor are treating patients by combining cord blood from multiple donors. They've found this increases the number of stem cells and provides faster recovery. Amanda's transfusion was from a baby whose mother donated six years earlier. The procedure completely cured her cancer and blood disorder.

Originally posted here:
Cord blood infusion saves woman's life